Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 12, 2003, Pages 3846-3852

  Sauder, Daniel N ^a,c   Smith, Michael H ^b   Senta McMillian, Therese ^b   Soria, Inmaculada ^b   Meng, Tze Chiang ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b 3M COMPANY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; PLACEBO; RESIQUIMOD;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; FOREARM; GEL; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; LANGERHANS CELL; LYMPHOCYTIC INFILTRATION; MALE; MEDICAL ASSESSMENT; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN BIOPSY; T LYMPHOCYTE; TISSUE SECTION; WILCOXON SIGNED RANKS TEST;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GELS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RNA, MESSENGER; SINGLE-BLIND METHOD; SKIN;

EID: 0344443213     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.12.3846-3852.2003     Document Type: Article

References (21)

1. Arany, I., S. K. Tyring, M. A. Stanley, M. A. Tomai, R. L. Miller, M. H. Smith, D. J. McDermott, and H. B. Slade. 1999. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antivir. Res. 43:55-63.
2. Barker, J. N. W. N., M. L. Jones, R. S. Mitra, E. Crockett-Torabe, J. C. Fantone, S. L. Kunkel, J. S. Warren, V. M. Dixit, and B. J. Nickoloff. 1991. Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am. J. Pathol. 139:869-876.
3. Beutner, K. R., S. K. Tyring, K. F. Trofatter, Jr., J. M. Douglas, S. Spruance, M. L. Owens, T. L. Fox, A. J. Hougham, and K. A. Schmitt. 1998. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob. Agents Chemother. 42:789-794.
4. Burns, R. P., B. Ferbel, M. Tomai, R. Miller, and A. A. Gaspari. 2000. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin. Immunol. 94:13-23.
5. Edwards, L., A. Ferenczy, L. Eron, D. Baker, M. L. Owens, T. L. Fox, A. J. Hougham, and K. A. Schmitt. 1998. Self administered topical 5% imiquimod cream for external anogenital warts. Arch. Dermatol. 134:25-30.
6. Gibson, S. J., L. M. Imbertson, T. L. Wagner, T. L. Testerman, M. J. Reiter, R. M. Miller, and M. A. Tomai. 1995. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J. Interferon Cytokine Res. 15:537-545.
7. Gibson, S. J., J. M. Lindh, T. R. Riter, R. M. Gleason, L. M. Rogers, A. E. Fuller, J. L. Oesterich, K. B. Gorden, X. Qiu, S. W. McKane, R. J. Noelle, R. L. Miller, R. M. Kedl, P. Fitgerald-Bocarsly, M. A. Tomai, and J. P. Vasilakos. 2002. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 218:74-86.
8. Gottlieb, M., and M. Charko. 1987. Silver staining of native and denatured eukaryotic DNA in agarose gels. Anal. Biochem. 165:33-37.
9. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196-200.
10. Imbertson, L. M., J. M. Beaurline, A. M. Couture, S. J. Gibson, R. M. A. Smith, R. L. Miller, M. J. Reiter, T. L. Wagner, and M. A. Tomai. 1998. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Investig. Dermatol. 110:734-739.
11. Ito, T., R. Amakawa, T. Kaisho, H. Hemmi, K. Tajima, K. Uehira, Y. Ozaki, H. Tomizawa, S. Akira, and S. Fukuhara. 2002. Interferon-α and interleukin-12 are induced differentially by toll-like receptor 7 ligand in human blood dendritic cell subsets. J. Exp. Med. 11:1507-1512.
12. Jurk, M., F. Heil, J. Vollmer, C. Schetter, A. M. Krieg, H. Wagner, G. Lipford, and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3:499.
13. Kondo, S., T. Kono, D. N. Sauder, and R. C. Mckenzie. 1993. Il-8 gene expression and production in human keratinocytes and their modulation by UVB, J. Investig. Dermatol. 101:690-694.
14. Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T Horn, K. B. Mullis, and H. A. Erlich. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487-491.
15. Suzuki, H., B. Wang, G. M. Shivji, P. Toto, P. Amerio, M. A. Tomai, R. L. Miller, and D. N. Sauder. 2000. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J. Investig. Dermatol. 114: 135-141.
16. Testerman, T. L., J. F. Gerster, L. M. Imbertson, M. J. Reiter, R. L. Miller, S. J. Gibson, T. L. Wagner, and M. A. Tomai. 1995. Cytokine induction by the immunomodulators imiquimod and S-27609. J. Leukoc. Biol. 58:365-372.
17. Tomai, M. A., S. J. Gibson, L. M. Imbertson, R. L. Miller, P. E. Myhre, M. J. Reiter, J. M. Beaurline, J. F. Gerster, and V. L. Horton. 1995, Immunomodulating and antiviral activities of the imidazoquinolines S-28463. Antivir. Res. 28:253-264.
18. Tonneson, M. G. 1989. Neutrophil-endothelial cell interactions: mechanisms of neutrophil adherence to vascular endothelium. J. Investig. Dermatol. 93(2 Suppl.):53S-58S.
19. Tyring, S. K., I. Arany, M. A. Stanley, M. A. Tomai, R. L. Miller, M. H. Smith, D. J. McDermott, and H. B. Slade. 1998. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J. Infect. Dis. 187:551-555.
20. Wagner, T. L., V. L. Horton, G. L. Carlson, P. E. Myhre, S. J. Gibson, L. M. Imbertson, and M. A. Tomai. 1997. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 9:837-845.
21. Witt, P. L., P. J. Ritch, D. Reding, T. L. McAuliffer, S. E. Grossberg, and E. C. Borden. 1993. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res. 53:5176-5180.